BioSpace News Archive

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that Arcutis Cares, the first ever patient assistance program for a topical psoriasis product, is open for enrollment.

CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster presentation at the upcoming European Society of Cardiology (ESC) Congress taking place August 26-29, 2022, virtually and live in Barcelona, Spain.

Innovative biotechnology company specializing in new drug discovery and development, Avelos Therapeutics, has received a glowing endorsement from the venture capital community by raising $8 million.

Becton, Dickinson and Company (NYSE: BDX) (the " Company " or " BD ") today announced the early tender results for its previously announced Tender Offers (as defined below) to purchase for cash certain of its outstanding debt securities listed in the table below.

MAIA Biotechnology, Inc. today reported financial results for the second quarter ended June 30, 2022, and provided a corporate update.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company announced that the first patient has been randomized in the clinical trial to evaluate anti-tumor necrosis factor (TNF) for patients with early-stage, pain predominant frozen shoulder.

RegeneRx Biopharmaceuticals, Inc. has issued a Letter to Stockholders updating development of product candidates.

Calyptus Pharmaceuticals, Inc., (“Calyptus”) announced that it entered into an agreement with Provepharm SAS (“Provepharm”), to accelerate the development, marketing and distribution of a complex injectable product used in acute care settings.

Ocelot Bio, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapeutics to treat complications of end-stage liver disease (ESLD), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its lead candidate OCE-205 for the treatment of hepatorenal syndrome.

Leucadia Therapeutics, a company working to cure Alzheimer’s disease, has hired a global chief medical officer practiced in skull base neurosurgery needed to implant the company’s revolutionary Arethusta® device, which drains disease-causing toxins from the brain.